FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2075152022> ?p ?o ?g. }

• W2075152022 endingPage "480" @default.
• W2075152022 startingPage "470" @default.
• W2075152022 abstract "•A protein-based MenB vaccine, Bexsero®, was licensed in Europe in 2013. •We assessed the potential use of Bexsero® to prevent secondary MenB cases. •The number needed to vaccinate (NNV) was high even in the most favourable scenario. •Bexsero® may have a role in preventing secondary MenB cases in clusters and outbreaks. Objectives To assess the potential use of a protein-based meningococcal group B (MenB) vaccine (Bexsero®) in addition to antibiotic chemoprophylaxis for preventing secondary cases. Methods Published studies on the risk of secondary meningococcal infections were used to estimate the numbers needed to vaccinate (NNV) with Bexsero® to prevent a secondary case in household and educational settings. Results Most secondary cases occur within a few days of diagnosis in the index case. Unlike conjugate vaccines, early protection offered after a single dose of Bexsero® is likely to be low, particularly in young children, who are at higher risk of secondary infection. NNV was dependent on predicted meningococcal strain coverage, estimated onset of protection after one Bexsero® dose and estimated vaccine efficacy. Even in the most favourable scenario where we assume the vaccine is administered within 4 days of the index case and prevents 90% of cases occurring after 14 days, the NNV for household contacts was >1000. NNV in educational settings was much higher. Conclusions The estimated NNV should be taken into account when deciding policy to recommend Bexsero® for close contacts of single cases in household or educational settings. Bexsero® may have a protective role in clusters and outbreaks. To assess the potential use of a protein-based meningococcal group B (MenB) vaccine (Bexsero®) in addition to antibiotic chemoprophylaxis for preventing secondary cases. Published studies on the risk of secondary meningococcal infections were used to estimate the numbers needed to vaccinate (NNV) with Bexsero® to prevent a secondary case in household and educational settings. Most secondary cases occur within a few days of diagnosis in the index case. Unlike conjugate vaccines, early protection offered after a single dose of Bexsero® is likely to be low, particularly in young children, who are at higher risk of secondary infection. NNV was dependent on predicted meningococcal strain coverage, estimated onset of protection after one Bexsero® dose and estimated vaccine efficacy. Even in the most favourable scenario where we assume the vaccine is administered within 4 days of the index case and prevents 90% of cases occurring after 14 days, the NNV for household contacts was >1000. NNV in educational settings was much higher. The estimated NNV should be taken into account when deciding policy to recommend Bexsero® for close contacts of single cases in household or educational settings. Bexsero® may have a protective role in clusters and outbreaks." @default.
• W2075152022 created "2016-06-24" @default.
• W2075152022 creator A5019073409 @default.
• W2075152022 creator A5046888535 @default.
• W2075152022 creator A5053121427 @default.
• W2075152022 creator A5059188706 @default.
• W2075152022 creator A5065434292 @default.
• W2075152022 creator A5072710559 @default.
• W2075152022 creator A5076914911 @default.
• W2075152022 date "2014-11-01" @default.
• W2075152022 modified "2023-09-27" @default.
• W2075152022 title "Preventing secondary cases of invasive meningococcal capsular group B (MenB) disease using a recently-licensed, multi-component, protein-based vaccine (Bexsero®)" @default.
• W2075152022 cites W1968258387 @default.
• W2075152022 cites W1979516665 @default.
• W2075152022 cites W1980477418 @default.
• W2075152022 cites W1981537887 @default.
• W2075152022 cites W1985306230 @default.
• W2075152022 cites W1987922572 @default.
• W2075152022 cites W2023036154 @default.
• W2075152022 cites W2025973886 @default.
• W2075152022 cites W2030879365 @default.
• W2075152022 cites W2043427342 @default.
• W2075152022 cites W2072220396 @default.
• W2075152022 cites W2103034759 @default.
• W2075152022 cites W2104702495 @default.
• W2075152022 cites W2109560424 @default.
• W2075152022 cites W2116680478 @default.
• W2075152022 cites W2118619617 @default.
• W2075152022 cites W2122656158 @default.
• W2075152022 cites W2136233777 @default.
• W2075152022 cites W2137432959 @default.
• W2075152022 cites W2139115435 @default.
• W2075152022 cites W2141001286 @default.
• W2075152022 cites W2143988742 @default.
• W2075152022 cites W2151895962 @default.
• W2075152022 cites W2338950842 @default.
• W2075152022 doi "https://doi.org/10.1016/j.jinf.2014.07.002" @default.
• W2075152022 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25043395" @default.
• W2075152022 hasPublicationYear "2014" @default.
• W2075152022 type Work @default.
• W2075152022 sameAs 2075152022 @default.
• W2075152022 citedByCount "9" @default.
• W2075152022 countsByYear W20751520222015 @default.
• W2075152022 countsByYear W20751520222016 @default.
• W2075152022 countsByYear W20751520222017 @default.
• W2075152022 countsByYear W20751520222019 @default.
• W2075152022 countsByYear W20751520222020 @default.
• W2075152022 crossrefType "journal-article" @default.
• W2075152022 hasAuthorship W2075152022A5019073409 @default.
• W2075152022 hasAuthorship W2075152022A5046888535 @default.
• W2075152022 hasAuthorship W2075152022A5053121427 @default.
• W2075152022 hasAuthorship W2075152022A5059188706 @default.
• W2075152022 hasAuthorship W2075152022A5065434292 @default.
• W2075152022 hasAuthorship W2075152022A5072710559 @default.
• W2075152022 hasAuthorship W2075152022A5076914911 @default.
• W2075152022 hasConcept C116675565 @default.
• W2075152022 hasConcept C159047783 @default.
• W2075152022 hasConcept C159654299 @default.
• W2075152022 hasConcept C203014093 @default.
• W2075152022 hasConcept C22070199 @default.
• W2075152022 hasConcept C2776645655 @default.
• W2075152022 hasConcept C2778458888 @default.
• W2075152022 hasConcept C2780454893 @default.
• W2075152022 hasConcept C2780801004 @default.
• W2075152022 hasConcept C523546767 @default.
• W2075152022 hasConcept C54355233 @default.
• W2075152022 hasConcept C71924100 @default.
• W2075152022 hasConcept C86803240 @default.
• W2075152022 hasConceptScore W2075152022C116675565 @default.
• W2075152022 hasConceptScore W2075152022C159047783 @default.
• W2075152022 hasConceptScore W2075152022C159654299 @default.
• W2075152022 hasConceptScore W2075152022C203014093 @default.
• W2075152022 hasConceptScore W2075152022C22070199 @default.
• W2075152022 hasConceptScore W2075152022C2776645655 @default.
• W2075152022 hasConceptScore W2075152022C2778458888 @default.
• W2075152022 hasConceptScore W2075152022C2780454893 @default.
• W2075152022 hasConceptScore W2075152022C2780801004 @default.
• W2075152022 hasConceptScore W2075152022C523546767 @default.
• W2075152022 hasConceptScore W2075152022C54355233 @default.
• W2075152022 hasConceptScore W2075152022C71924100 @default.
• W2075152022 hasConceptScore W2075152022C86803240 @default.
• W2075152022 hasFunder F4320309229 @default.
• W2075152022 hasIssue "5" @default.
• W2075152022 hasLocation W20751520221 @default.
• W2075152022 hasLocation W20751520222 @default.
• W2075152022 hasOpenAccess W2075152022 @default.
• W2075152022 hasPrimaryLocation W20751520221 @default.
• W2075152022 hasRelatedWork W1989410606 @default.
• W2075152022 hasRelatedWork W2082930259 @default.
• W2075152022 hasRelatedWork W2109381880 @default.
• W2075152022 hasRelatedWork W2159670176 @default.
• W2075152022 hasRelatedWork W2418126753 @default.
• W2075152022 hasRelatedWork W2901449408 @default.
• W2075152022 hasRelatedWork W3034875971 @default.
• W2075152022 hasRelatedWork W4283027788 @default.
• W2075152022 hasRelatedWork W4301330806 @default.
• W2075152022 hasRelatedWork W1988012188 @default.
• W2075152022 hasVolume "69" @default.

• next